No quarterly revenue total was found in Avalyn Pharma Inc.'s SEC filings.
Avalyn Pharma Inc. (AVLN) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$26.3 million. As of Jun 30, 2026 it held $413.5 million in cash and investments and $17.1 million in total debt.
Revenue
—
Net income
$-28.93M
-7.7% vs prior quarter
Operating cash flow
$-26.08M
+12.8% vs prior quarter
Free cash flow
$-26.34M
+12.8% vs prior quarter
EPS
$-0.98
+95.5% vs prior quarter
Dividend per share
None
Shares outstanding
44.33M
+0.0% vs prior quarter
Net cash
$396.42M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AVLN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1540171
- Former names
- Genoa Pharmaceuticals, Inc. (until May 24, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
|---|---|---|
| Operating income | -$31.3M | -$27.9M |
| Net income | -$28.9M | -$26.9M |
| Diluted EPS | -$0.98 | -$21.83 |
| Operating cash flow | -$26.1M | -$29.9M |
| Free cash flow | -$26.3M | -$30.2M |
| Total assets | $425.4M | $135.7M |
| Total liabilities | $27.1M | $27.7M |
| Stockholders' equity | $398.3M | -$264.2M |
| Cash and investments | $413.5M | $123.1M |
| Total debt | $17.1M | $16.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Sep 16, 2026 | Sep 15, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 1, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 17, 2026 | Jun 17, 2026 |
| 10-Q | Quarterly report | Jun 3, 2026 | Mar 31, 2026 |
All 63 Avalyn Pharma Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.